Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2018
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2018
SUMMARY
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 52 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 5, 10, 1, 23 and 8 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Gastroesophageal (GE) Junction Carcinomas, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Vaginal Cancer, Vulvar Cancer, Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anal Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Ewing Sarcoma, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Meningioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
The latest report Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects.
Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) H2 2018‘, provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics. The report provides comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects.Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 52 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 5, 10, 1, 23 and 8 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Gastroesophageal (GE) Junction Carcinomas, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Vaginal Cancer, Vulvar Cancer, Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anal Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Ewing Sarcoma, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Meningioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 52 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 5, 10, 1, 23 and 8 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Gastroesophageal (GE) Junction Carcinomas, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Vaginal Cancer, Vulvar Cancer, Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anal Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Ewing Sarcoma, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Meningioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
The latest report Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects.
Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) H2 2018‘, provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics. The report provides comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects.Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 52 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 5, 10, 1, 23 and 8 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Gastroesophageal (GE) Junction Carcinomas, Muscle Invasive Bladder Cancer (MIBC), Nasopharyngeal Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Vaginal Cancer, Vulvar Cancer, Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anal Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Ewing Sarcoma, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Meningioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones
Appendix
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aduro BioTech Inc, H2 2018
Pipeline by Agenus Inc, H2 2018
Pipeline by Alligator Bioscience AB, H2 2018
Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2018
Pipeline by Biocad, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CBT Pharmaceuticals Inc, H2 2018
Pipeline by Cellective BioTherapy Inc, H2 2018
Pipeline by Cold Genesys Inc, H2 2018
Pipeline by Five Prime Therapeutics Inc, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Immunocore Ltd, H2 2018
Pipeline by Immunwork Inc, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by JHL Biotech Inc, H2 2018
Pipeline by MacroGenics Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by OncoImmune Inc, H2 2018
Pipeline by PharmAbcine Inc, H2 2018
Pipeline by Premier Biomedical Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Replimune Ltd, H2 2018
Pipeline by Serometrix LLC, H2 2018
Pipeline by Stcube Inc, H2 2018
Pipeline by Sutro Biopharma Inc, H2 2018
Pipeline by Tikcro Technologies Ltd, H2 2018
Pipeline by Xencor Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aduro BioTech Inc, H2 2018
Pipeline by Agenus Inc, H2 2018
Pipeline by Alligator Bioscience AB, H2 2018
Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2018
Pipeline by Biocad, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CBT Pharmaceuticals Inc, H2 2018
Pipeline by Cellective BioTherapy Inc, H2 2018
Pipeline by Cold Genesys Inc, H2 2018
Pipeline by Five Prime Therapeutics Inc, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Immunocore Ltd, H2 2018
Pipeline by Immunwork Inc, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by JHL Biotech Inc, H2 2018
Pipeline by MacroGenics Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by OncoImmune Inc, H2 2018
Pipeline by PharmAbcine Inc, H2 2018
Pipeline by Premier Biomedical Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Replimune Ltd, H2 2018
Pipeline by Serometrix LLC, H2 2018
Pipeline by Stcube Inc, H2 2018
Pipeline by Sutro Biopharma Inc, H2 2018
Pipeline by Tikcro Technologies Ltd, H2 2018
Pipeline by Xencor Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Aduro BioTech Inc
Agenus Inc
Alligator Bioscience AB
BeyondSpring Pharmaceuticals Inc
Biocad
Bristol-Myers Squibb Co
CBT Pharmaceuticals Inc
Cellective BioTherapy Inc
Cold Genesys Inc
Five Prime Therapeutics Inc
GigaGen Inc
Immunocore Ltd
Immunwork Inc
Innovent Biologics Inc
JHL Biotech Inc
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
OncoImmune Inc
PharmAbcine Inc
Premier Biomedical Inc
Regeneron Pharmaceuticals Inc
Replimune Ltd
Serometrix LLC
Stcube Inc
Sutro Biopharma Inc
Tikcro Technologies Ltd
Xencor Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Aduro BioTech Inc
Agenus Inc
Alligator Bioscience AB
BeyondSpring Pharmaceuticals Inc
Biocad
Bristol-Myers Squibb Co
CBT Pharmaceuticals Inc
Cellective BioTherapy Inc
Cold Genesys Inc
Five Prime Therapeutics Inc
GigaGen Inc
Immunocore Ltd
Immunwork Inc
Innovent Biologics Inc
JHL Biotech Inc
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
OncoImmune Inc
PharmAbcine Inc
Premier Biomedical Inc
Regeneron Pharmaceuticals Inc
Replimune Ltd
Serometrix LLC
Stcube Inc
Sutro Biopharma Inc
Tikcro Technologies Ltd
Xencor Inc
